Research Departments & Organizations
As neurodegenerative diseases pose a huge challenge to our aging society, novel and creative approaches are needed to illuminate their pathogenesis, detect the diseases at early stages, and monitor therapeutic effects of testing drugs. We are developing and testing PET imaging approaches that directly measure biochemical or proteomic changes in brain. Doing so requires integration of medicinal chemistry, radiochemistry, PET imaging, and pharmacology through broad collaborations.
Imaging research New Haven, United States (2018)
PET Imaging for Early Detection of Alzheimer's Disease: From Pathologic to Physiologic Biomarkers.
Bao W, Jia H, Finnema S, Cai Z, Carson RE, Huang YH. PET Imaging for Early Detection of Alzheimer's Disease: From Pathologic to Physiologic Biomarkers. PET Clinics 2017, 12:329-350. 2017
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases.
Cai Z, Li S, Matuskey D, Nabulsi N, Huang Y. PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. Neuroscience Letters 2019, 691:44-50. 2019